Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![JChengWSJ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::382788364.png) Jonathan Cheng [@JChengWSJ](/creator/twitter/JChengWSJ) on x 85.9K followers
Created: 2025-07-02 01:53:10 UTC

“Ten years ago, what we saw coming out of China were more follow-on, similar drugs, less differentiation. What we are seeing today is fundamentally different: first-in-class, best-in-class,” Gilead Sciences’ CFO, Andrew Dickinson, said in January.



XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1940227213829562661/c:line.svg)

**Related Topics**
[drugs](/topic/drugs)
[china](/topic/china)
[gilead sciences](/topic/gilead-sciences)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/JChengWSJ/status/1940227213829562661)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

JChengWSJ Avatar Jonathan Cheng @JChengWSJ on x 85.9K followers Created: 2025-07-02 01:53:10 UTC

“Ten years ago, what we saw coming out of China were more follow-on, similar drugs, less differentiation. What we are seeing today is fundamentally different: first-in-class, best-in-class,” Gilead Sciences’ CFO, Andrew Dickinson, said in January.

XXXXX engagements

Engagements Line Chart

Related Topics drugs china gilead sciences stocks healthcare

Post Link

post/tweet::1940227213829562661
/post/tweet::1940227213829562661